Healthcare

RMPIA
By

David Katz

 | Jan 8, 2017 | 2:00 PM EST
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
RMPIA
By

David Katz

 | Jan 6, 2017 | 7:00 AM EST
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
By

Bret Jensen

 | Jan 5, 2017 | 12:00 PM EST
M&A activity should perk up substantially in the small and mid-cap space this year.
By

Bruce Kamich

 | Jan 4, 2017 | 10:59 AM EST
Charts suggest to be prepared for a shallow pullback.
By

Bret Jensen

 | Jan 3, 2017 | 1:30 PM EST
This biopharma company's Relistor drug should send revenues sharply higher this year.
By

Chris Laudani

 | Jan 3, 2017 | 12:00 PM EST
ABT could be on course for 10% earnings growth this year, but will investors reward the company with a higher share price?
RMPIA
By

Bret Jensen

 | Jan 3, 2017 | 11:00 AM EST
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
By

Bret Jensen

 | Dec 30, 2016 | 11:00 AM EST
This small-cap Israeli biotech has some important catalysts coming up in 2017.
By

Robert Moreno

 | Dec 30, 2016 | 10:17 AM EST
Still, volume and positive money flow will need to improve to sustain a breakout move in the name.
By

Jim Collins

 | Dec 29, 2016 | 4:00 PM EST
There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.
EMN put in its third straight monthly high last week. The stock also closed ever so slight...
FIBOCALL: CSX CSX gap opening higher today, based on news. Our overshoot level @ 41.92 a...
Market is little changed as we are on the cusp of a presidential turnover.  Oil up a ...
join me after the day of trading for a webinar talking about volume, how to analyze it and...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.